[C1q tumor necrosis factor-related protein 6 (CTRP6) inhibits the proliferation and migration of ovarian cancer cells].
To explore the role of C1q tumor necrosis factor-related protein 6 (CTRP6) in the proliferation and migration of ovarian cancer cells. ELISA was used to detect the serum CTRP6 contents in ovarian cancer patients and healthy volunteers, and CTRP6 levels in the supernatants of SKOV3, 3AO and HO8910 epithelial ovarian cancer cell lines and IOSE80 normal ovarian epithelial cells. Recombinant human CTRP6 protein was applied to treat HO8910 cells. After incubation for 48 hours, ELISA was used to detect the levels of interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) in the supernatants. The proliferation of HO8910 cells were detected by CCK-8 assay and the ability of invasion was determined by Transwell(TM) invasion assay. CTRP6 siRNA or anti-CTRP6 antibody was used to treat HO8910 cells, and then the ability of proliferation was also detected by CCK-8 assay and the ability of migration was evaluated by wound healing experiment. The level of CTRP6 decreased in the sera of the patients with ovarian cancer and the supernatants of epithelial ovarian cancer cells. The levels of IL-8 and VEGF were reduced by the recombinant CTRP6 protein treatment, and the cell proliferation and invasion were also inhibited. CTRP6 siRNA or anti-CTRP6 antibody treatment promoted cell proliferation and migration. The level of CTRP6 dropped in the sera of the patients with ovarian cancer as well as in the supernatants of epithelial ovarian cancer cells. CTRP6 could inhibit the proliferation and migration of ovarian cancer cells via blocking IL-8/VEGF pathway.